文献速递神经肿瘤小儿神经外科与脑积水神经重症

发育免疫劫持:儿童脑肿瘤中的炎症与免疫失调

Hijacking Developmental Immunity: Inflammation and Immune Dysregulation in Pediatric Brain Tumors.
PubMed 文献 · Neuro Oncol · 2026-10-14

本文综述儿童脑肿瘤(PBT)在发育受限的免疫微环境中如何利用生理性免疫成熟程序实现免疫逃逸、维持慢性炎症并促进治疗抵抗。以髓母细胞瘤、儿童胶质瘤、非典型畸胎样/横纹肌样瘤及室管膜瘤为代表,结合发育神经生物学、肿瘤免疫学及多组学研究,讨论新兴多模式免疫治疗与下一代CAR T细胞策略。

要点

  • PBT起源于神经发育程序紊乱,其免疫微环境具耐受性、表观遗传可塑性且易被肿瘤劫持。
  • PBT利用早期免疫系统并限制其成熟以逃避检测,同时依赖持续炎症促进生长和耐药。
  • 免疫治疗在多数PBT中尚未显示一致临床获益,需基于肿瘤-免疫互作设计多模式策略。

核心结论

  • 儿童脑肿瘤劫持发育期免疫成熟程序,建立免疫逃逸、维持慢性炎症并促进治疗抵抗。
  • 免疫治疗在多数儿童脑肿瘤中尚未显示一致临床获益,需理性设计多模式策略。

研究设计与样本

  • 综述,以髓母细胞瘤、儿童胶质瘤、非典型畸胎样/横纹肌样瘤及室管膜瘤为代表实体。
  • 整合发育神经生物学、肿瘤免疫学及新兴多组学研究视角。

主要发现

  • 儿童脑肿瘤在耐受性、表观遗传可塑性且易被肿瘤利用的发育受限免疫景观中演化。
  • 除分子异质性外,肿瘤免疫微环境对临床结局有重要影响。
  • 儿童脑肿瘤利用生理性免疫成熟程序建立免疫逃逸、维持慢性炎症并促进治疗抵抗。

临床怎么用

  • 关注靶向肿瘤相关髓系细胞群体和关键炎症调节因子的治疗途径。
  • 关注当前临床研究中的多模式免疫治疗策略与下一代CAR T细胞方法。
  • 需改进临床前模型并优化患者分层以指导治疗策略的理性设计。

局限性

  • 免疫治疗在多数儿童脑肿瘤中尚未显示一致临床获益。
  • 当前临床前模型存在局限,需改进以支持转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric brain tumors (PBTs) remain a leading cause of cancer-related mortality in children, underscoring the need for more effective therapeutic strategies. These tumors arise from disrupted neurodevelopmental programs and evolve within a developmentally constrained immune landscape that is tolerogenic, epigenetically plastic, and susceptible to tumor-mediated co-option. Increasing evidence indicates that, besides molecular heterogeneity, the tumor immune microenvironment critically influences clinical outcomes. Despite its therapeutic promise, immunotherapy has yet to demonstrate consistent clinical benefit in most PBTs, highlighting the need for rational multimodal strategies guided by deeper understanding of tumor-immune interactions in the developing brain. To provide a comprehensive perspective on fetal immune ontogeny and its tumor-driven dysregulation we used medulloblastoma, pediatric gliomas, atypical teratoid/rhabdoid tumors, and ependymoma as representative entities. Drawing on insights from developmental neurobiology, tumor immunology, and emerging multi-omic studies, we outline how PBTs exploit physiological immune maturation programs to establish immune evasion, sustain chronic inflammation, and promote therapy resistance. We further discuss emerging multimodal immunotherapeutic strategies and next-generation CAR T-cell approaches currently under clinical investigation. In addition, we highlight therapeutic avenues such as targeting tumor-associated myeloid populations and key inflammatory regulators that may offer promising opportunities for future clinical translation. We believe this Review will help address current limitations in preclinical models, improve patient stratification and guide rational design of therapeutic strategies. Brain tumors are a leading cause of cancer-related death in children. Immune-based treatments have made progress against adult cancers. However, these treatments have not worked as well for pediatric brain tumors (PBTs). In this Review, we used insights from brain development, tumor-immune interaction, and large-scale molecular studies. We propose that PBTs exploit the early-life immune system and restrict its maturation to avoid detection. PBTs also rely on persistent inflammation to grow and resist treatment. We highlight emerging treatment strategies that target these immune states and inflammatory molecules. We believe this study can help guide better therapy design in the future.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Roy R, Kerl K. Hijacking Developmental Immunity: Inflammation and Immune Dysregulation in Pediatric Brain Tumors. Neuro Oncol. 2026. PMID: 42872492. doi:10.1093/neuonc/noag168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。